The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu(erb B-2) oncogene overexpression in cancer cells
Open accessAbstract
Fatty acid synthase (FAS) activity is a potential therapeutic target to treat cancer and obesity. Here, we have identified a molecular link between FAS and HER2(erb B-2) oncogene, a marker for poor prognosis that is overexpressed in 30% of breast and ovarian cancers. Pharmacological FAS inhibitors cerulenin and C75 were found to suppress p185HER2oncoprotein expression and tyrosine-kinase activity in breast and ovarian HER2 overexpressors. Similarly, p185HER2expression was dramatically down-regulated when FAS gene expression was silenced by using the highly sequence-specific mechanism of RNA interference (RNAi). Pharmacological and RNAi-mediated silencing of FAS specifically down-regulated HER2 mRNA and, concomitantly, caused a prominent up-regulation of PEA3, a transcriptional repressor of HER2. A cytoplasmic redistribution of p185HER2was associated with marked morphological changes of FAS RNAi-transfected cells, whereas chemical inhibitors of FAS promoted a striking nuclear accumulation of p185HER2. The simultaneous targeting of FAS and HER2 by chemical FAS inhibitors and the humanized antibody directed against p185HER2trastuzumab, respectively, was synergistically cytotoxic toward HER2 overexpressors. Similarly, concurrent RNAi-mediated silencing of FAS and HER2 genes synergistically stimulated apoptotic cell death in HER2 overexpressors. p185HER2was synergistically down-regulated after simultaneous inhibition of FAS and HER2 by either pharmacological inhibitors or small interfering RNA. These findings provide evidence of an active role of FAS in cancer evolution by specifically regulating oncogenic proteins closely related to malignant transformation, strongly suggesting that HER2 oncogene may act as the key molecular sensor of energy imbalance after the perturbation of tumor-associated FAS hyperactivity in cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,676
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology
Kuhajda, F. P. (2000) · Nutrition · doi:10.1016/s0899-9007(99)00266-x · Cited by 788
Fatty acid synthesis: a potential selective target for antineoplastic therapy
Kuhajda, F. P., Jenner, K., Wood, F. D., Hennigar, R. A., Jacobs, L. B., Dick, J. D., & Pasternack, G. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6379 · Cited by 705
Cited by
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941
Self-citationThe multifaceted roles of fatty acid synthesis in cancer
Röhrig, F., & Schulze, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.89 · Cited by 1,651
Reprogramming of fatty acid metabolism in cancer
Koundouros, N., & Poulogiannis, G. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0650-z · Cited by 1,614
Targeting cellular metabolism to improve cancer therapeutics
Zhao, Y., Butler, E. B., & Tan, M. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.60 · Cited by 989
Bian, X., Liu, R., Meng, Y., Xing, D., Xu, D., & Lu, Z. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201606 · Cited by 983
Lipid metabolism reprogramming and its potential targets in cancer
Cheng, C., Geng, F., Cheng, X., & Guo, D. (2018) · Cancer Communications · doi:10.1186/s40880-018-0301-4 · Cited by 850
Fatty Acid Synthase and Cancer: New Application of an Old Pathway
Kuhajda, F. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4673 · Cited by 647
Increased lipogenesis in cancer cells: new players, novel targets
Swinnen, J. V., Brusselmans, K., & Verhoeven, G. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000232894.28674.30 · Cited by 610
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy
Mashima, T., Seimiya, H., & Tsuruo, T. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605007 · Cited by 555
Fatty Acid Synthase As a Potential Therapeutic Target in Cancer
Flavin, R., Peluso, S., Nguyen, P. L., & Loda, M. (2010) · Future Oncology · doi:10.2217/fon.10.11 · Cited by 545
Hilvo, M., Denkert, C., Lehtinen, L., Müller, B., Brockmöller, S., Seppänen-Laakso, T., Budczies, J., Bucher, E., Yetukuri, L., Castillo, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3894 · Cited by 532
Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity
Yoon, H., Shaw, J. L., Haigis, M. C., & Greka, A. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.027 · Cited by 510
Gong, Y., Ji, P., Yang, Y.-S., Xie, S., Yu, T.-J., Xiao, Y., Jin, M.-L., Ma, D., Guo, L.-W., Pei, Y.-C., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.012 · Cited by 467
The role of phosphatidylcholine and choline metabolites to cell proliferation and survival
Ridgway, N. D. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.735643 · Cited by 339
Plathow, C., & Weber, W. A. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045930 · Cited by 328
Glycerolipid Metabolism and Signaling in Health and Disease
Prentki, M., & Madiraju, S. R. M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0007 · Cited by 326
Zhang, D., Tai, L. K., Wong, L. L., Chiu, L.-L., Sethi, S. K., & Koay, E. S. C. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400221-mcp200 · Cited by 312
Metformin: Multi-faceted protection against cancer
Del Barco, S., Vazquez-Martin, A., Cufí, S., Oliveras-Ferraros, C., Bosch-Barrera, J., Joven, J., Martin-Castillo, B., & Menendez, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.387 · Cited by 302
Self-citationFatty acid synthase (FASN) as a therapeutic target in breast cancer
Menendez, J. A., & Lupu, R. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1381087 · Cited by 293
Self-citationTowards personalized treatment for early stage HER2-positive breast cancer
Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0299-9 · Cited by 287
Vazquez-Martin, A., Oliveras-Ferraros, C., & Menendez, J. A. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7499 · Cited by 250
Self-citationMonosaccharide-induced lipogenesis regulates the human hepatic sex hormone–binding globulin gene
Selva, D. M., Hogeveen, K. N., Innis, S. M., & Hammond, G. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32249 · Cited by 232
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions
Vernieri, C., Casola, S., Foiani, M., Pietrantonio, F., de Braud, F., & Longo, V. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0615 · Cited by 202
Kourtidis, A., Srinivasaiah, R., Carkner, R. D., Brosnan, M. J., & Conklin, D. S. (2009) · Breast Cancer Research · doi:10.1186/bcr2240 · Cited by 60
Multiplexing siRNAs to compress RNAi-based screen size in human cells
Martin, S. E., Jones, T. L., Thomas, C. L., Lorenzi, P. L., Nguyen, D. A., Runfola, T., Gunsior, M., Weinstein, J. N., Goldsmith, P. K., Lader, E., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm141 · Cited by 40
Glucose-sensitive acetylation of Seryl tRNA synthetase regulates lipid synthesis in breast cancer
Zhao, J., Bai, H., Li, X., Yan, J., Zou, G., Wang, L., Li, X., Liu, Z., Xiang, R., Yang, X.-L., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00714-0 · Cited by 27
Metadata
- Authors
- Menendez, J. A., Vellon, L., Mehmi, I., Oza, B. P., Ropero, S., Colomer, R., & Lupu, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-07-02
- Volume
- 101
- Issue
- 29
- Pages
- 10715-10720
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2039731227
- Cited by
- 327
- References
- 35
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.